Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis
Crossref DOI link: https://doi.org/10.1007/s12325-020-01426-7
Published Online: 2020-07-09
Published Print: 2020-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tafazzoli, Ali
Chavan, Ameya
Harty, Gerard
Moller, Jorgen
Wong, Schiffon L.
Funding for this research was provided by:
Merck KGaA
Text and Data Mining valid from 2020-07-09
Version of Record valid from 2020-07-09
Article History
Received: 3 June 2020
First Online: 9 July 2020